<DOC>
	<DOCNO>NCT00272051</DOCNO>
	<brief_summary>Purpose trial evaluate efficacy Xaliproden reduce neurotoxicity Oxaliplatin 5-FU/LV chemotherapy , patient metastatic colorectal carcinomaPrimary objective : Compare risk occurence grade 3-4 peripheral sensory neuropathy relative cumulative dose Oxaliplatin treatment group placebo group ; Compare response rate treatment group placebo group.Secondary objective : neurotoxicity parameter ( overall incidence , time dose onset , time recovery , change sensory action potential ) ; antitumoral efficacy ( progression-free survival , overall survival ) ; safety profile .</brief_summary>
	<brief_title>XENOX â€“ Evaluation Efficacy Xaliproden Reducing Neurotoxicity Oxaliplatin + 5-FU/LV Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically proven adenocarcinoma colon rectum age &gt; 18 year WHO performance status : 0,1,2 Signed write informed consent prior study entry Disease stage : metastatic disease amenable potentially curative treatment ( eg : inoperable metastatic disease ) Measurable disease No prior chemotherapeutic regimen metastatic disease ; prior adjuvant chemotherapy allow ( disease free interval end adjuvant therapy least 6 month ) Prior radiotherapy permit , complete least 3 week randomization , administer target lesion identify study Chemotherapeutic agent 5FU/LV 5FU/Levamizole part adjuvant therapy Prior therapy Oxaliplatin History cardiac toxicity 5FU/LV therapy myocardial infarction within 6 month study entry ; Known Dihydropyrimidine Dehydrogenase deficiency History intolerance appropriate antiemetic Concurrent active cancer originate primary site colon rectum Presence symptom suggest brain metastasis Known peripheral neuropathy Interstitial pneumonia extensive symptomatic fibrosis lung Allergy Xaliproden/excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Neurotoxicity syndrome</keyword>
	<keyword>Paresthesia</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Xaliproden</keyword>
</DOC>